Motif Bio Share Discussion Threads

[aughton 3] 29/8/2015 07:46

Who knows if it will still be here in 12 months

[regandharry5] 28/8/2015 22:52

Any buying should see gd movement on the share price. The potential for this is huge and cannot see the reason for selling at these prices.I know 12 months is a long time for some holders of aim stocks,but this will bring huge rewards for those that have the patience.

[victor2] 28/8/2015 16:50

Zeus and northlands are taking company on roadshow
starting next week seeing 15-20 institutional clients
would be amazed if we didnt see some buying on the
back of it already firmer this afternoon.

[timbo003] 28/8/2015 13:17

Motif Bio (LON:MTFB) – Speculative Buy

Half year results released yesterday were largely academic, detailing Total loss for the period of US$1.86m (US$0.55m), while cash and cash equivalents as at 30th June 2015 of US$2.8m (31st December 2014: nil). By comparison, operational highlights for the period were anything but, with the US Food and Drug Administration (FDA) agreed to Phase III trials of iclaprim, while partnering with a global leading CRO for Phase III clinical trials. Since the period end, it has also been granted QIDP designation by the FDA in ABSSSI and HABP, while independent tests by JMI Laboratories demonstrated iclaprim to be effective in vitro against a range of Gram-positive bacteria and 16 times more potent than trimethoprim. A successful placing on 22nd July 2015 raising £22m at 50 pence/share also left the group cash rich ahead of commencing the Phase III trials.

Our view: While the interim results told shareholders little that they did not already know, they do serve as a reminder of exactly why Beaufort is such a supporter of Motif shares. They present shareholders with a genuine ‘bonanza’ opportunity. Management is building exceptional value while making significant progress in preparation for commencing the Phase III trials. Iclaprim is being designed to be administered in hospitals as an intravenous infusion. A most urgent need for novel antibiotics effective against multi-drug resistant bacteria is in the hospital setting where patients often succumb to serious, life-threatening infections that require immediate treatment with the best available antibiotic has clearly been established. In the case of HABP, for example, mortality rates for infected patients are currently between 20% and 50% and, in response, Motif seeks to accelerate its speed to market by targeting commercialisation as a hospital product rather than through the wider medical community. Indeed, given the opportunity already identified in HABP and ABSSSI along with a number of other potential indications, the prospective market value for this novel antibiotic is very large indeed, potentially running in billions of US dollars. The much publicised global need for such new drugs means that iclaprim must already be under review by Big Pharma, with a view to farming-in to Motif’s opportunity in exchange for financing late stage development and subsequent commercialisation. Realistically, such an outcome might be expected before end-2016. The value this will accrue to Motif should then be quite considerable. Beaufort repeats its Speculative Buy rating for Motif Bio and confirms a price target of 110p/share.

[timbo003] 25/8/2015 17:29

A link to yesterday's ProactiveInvestor interview with Graham Lumsden on Iclaprim potency is now in the header.

Note: If you think you have heard it all somewhere before towards the end of the interview, you have! Someone seems to have messed up the editing and the dialogue from 4.45 is repeated at 6.30.

[singer8] 25/8/2015 16:33

WARNING pump and dump be operated by 21trader

[hazl] 25/8/2015 08:22

Quantum Pharma QP. a good prospect as well as here


IMO

[mdchand] 25/8/2015 07:51

Beaufort Broker note

Our view: These in-vitro results are genuinely impressive and develop confidence in iclaprim’s ability to successfully treat life threatening infections where currently available treatments are not fully effective due to resistance or side-effects. Reported minimum inhibitory concentrations (‘MICs’) demonstrate that iclaprim is active against Staphylococcus aureus at very low concentrations. The MIC50%, the minimum concentration of iclaprim required to kill 50% of tested bacteria, was 0.06 mcg/ml and the MIC90%, the minimum concentration of iclaprim required to kill 90% of tested bacteria, was 0.12 mcg/ml. Comparing this to data for other antibiotics against the same 1,178 strains of Staphylococcus aureus, 1 mcg/ml of vancomycin and 1 mcg/ml of linezolid was required to meet the MIC50% and MIC90% levels. Against methicillin-resistant Staphylococcus aureus (MRSA), iclaprim was also highly active: the MIC50% was 0.06 mcg/ml and the MIC90% was 0.5 mcg/ml. Given the opportunity already identified in HABP and ABSSSI together with a number of other potential indications, the prospective market value for this novel antibiotic is very large indeed, potentially running in billions of US$. The much publicised global need for such new drugs means that iclaprim must already be under review by Big Pharma, with a view to farming-in to Motif’s opportunity in exchange for financing late stage development and subsequent commercialisation. Realistically, such an outcome might be expected before end-2016. The value this will accrue to Motif should then be quite considerable. Beaufort repeats its Speculative Buy rating for Motif Bio and confirms a price target of 110p/share.

[hazl] 24/8/2015 07:57

Dr. David Huang, Chief Medical Officer at Motif, commented: "These encouraging new results confirm the Board's confidence in developing iclaprim to treat ABSSSI and HABP. We believe that iclaprim will prove to be an important option for treating these life threatening infections where currently available treatments are not fully effective due to resistance or side effects."

[regandharry5] 24/8/2015 07:49

Brilliant news, always thought it would be ,but nice to have it confirmed

[hazl] 19/8/2015 14:46

what a rollercoaster.... market not so good again now imo

[hazl] 19/8/2015 10:54

have a feeling things may recover a bit this afternoon on the general market as China stocks look better apparently

IMO

[andrbea] 18/8/2015 16:09

LONDON: In a major clampdown on unnecessary use of antibiotics, Britain has now decided to penalise doctors who go soft and give in to patient's demands for the wonder drugs that are fast becoming ineffective.

[hazl] 18/8/2015 15:47

Doctors penalised for over-subscribing antibiotics?

Seems latest idea.

'Doctors who dole out too many prescriptions should face disciplinary action says health watchdog' Telegraph.

IMO

[andrbea] 18/8/2015 12:01

some general reading:



and:
The consequences are so severe that in Greece and Italy about 70 per cent of patients are infected with bugs unable to be treated by normal antibiotics.

[regandharry5] 18/8/2015 10:53

Antibiotics in the news again, every time the over use of current antibiotics and how ineffiecent they are is raised the MTFB share price rises.

[hazl] 14/8/2015 10:51

interesting tho not specific to do with Motif bio

[regandharry5] 05/8/2015 17:43

Off topic, has anybody else had a problem with the Windows 10 running the Java software.
All I get is a window flagged up saying Java is not compatable with Windows 10.

[hazl] 30/7/2015 11:55

Just a bit of a retrace,in my opinion.
This company is working on some pretty essential stuff.
Just today in The Telegraph I read a similar article to the link below.
This is going to gain momentum I'm sure of it.

IMO




'Modern medicine is finished if the problem of antibiotic resistant germs is not confronted, the Chief Medical Officer has warned.

Dame Sally Davies said prescribing antibiotics for illnesses for which they won’t help was making the problem worse.

She has called before for the development of new antibiotics as the current ones get increasingly less effective.

She told the BBC Radio 4 Today programme:'

'Dame Sally was reacting to the publication of new research by the Wellcome Trust which shows public understanding of antimicrobial resistance is still lacking.

The researchers conducted a series of interviews and focus groups in London, Manchester and Birmingham.

They found that most people, if they had heard of antibiotic resistance at all, thought it was their body which becomes resistant to antibiotics, rather than the bacteria that cause drug-resistant infections.

This misconception often makes people feel like antibiotic resistance is someone else’s problem, the researchers said.'

[21trader] 30/7/2015 11:10

Taking on a heavyweight mm like Cantors is difficult, while they throw up bargains or stocks much cheaper they seem determined to force prices down in a lot of stocks atm and this one is no different.

So strong on the bid the other day at 64p now 55p offer they seem to have endless
stock to sell yet they never seem to offer much online. Is 50p placing price the support level now for this ?

[thejaba] 30/7/2015 10:31

quite a gap to be filled

[scott1000] 29/7/2015 21:47

Cheers, only shows properly when I'm on the laptop.. The phone app doesn't show it clearly for me personally.. Definitely worth a watch!

[timbo003] 29/7/2015 21:18

>>>>Scott/phowdo

There's a link to the June 10th Webinar in the header of this thread